Handel BioMarin Pharmaceutical Inc - BMRN CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Spænd | 0.88 | ||||||||
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.030779% | ||||||||
Short position, gebyr natten over
Short position overnight fee
Gå til platform | -0.013666% | ||||||||
Gebyr natten over, tid | 22:00 (UTC) | ||||||||
Min. handlet mængde | 1 | ||||||||
Valuta | USD | ||||||||
Margen | 20% | ||||||||
Aktiebørs | United States of America | ||||||||
Kommission på handel | 0% |
*Information provided by Capital.com
Biomarin Pharmaceutical Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Tidligere luk* | 112.62 |
Åben* | 112.65 |
1-Års Ændring* | 27.63% |
Dagens Spænd* | 111.69 - 113.28 |
52-Ugers Spænd | 70.73-117.77 |
Gennemsnitlig Volumen (10 dage) | 1.46M |
Gennemsnitlig Volumen (3 måneder) | 31.05M |
Market Cap | 20.85B |
P/E-forhold | 284.19 |
Udestående aktier | 185.85M |
Omsætning | 2.01B |
EPS | 0.39 |
Dividend (Udbytte %) | N/A |
Beta | 0.36 |
Næste indtjeningsopgørelse | Feb 21, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Luk | Change | Change (%) | Åben | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 111.72 | -0.63 | -0.56% | 112.35 | 113.68 | 111.21 |
Feb 2, 2023 | 112.62 | -3.05 | -2.64% | 115.67 | 116.34 | 111.50 |
Feb 1, 2023 | 116.50 | 2.14 | 1.87% | 114.36 | 116.68 | 113.19 |
Jan 31, 2023 | 115.12 | 1.18 | 1.04% | 113.94 | 115.38 | 113.94 |
Jan 30, 2023 | 114.47 | -1.80 | -1.55% | 116.27 | 116.93 | 114.14 |
Jan 27, 2023 | 116.79 | 1.47 | 1.27% | 115.32 | 117.56 | 115.32 |
Jan 26, 2023 | 116.58 | 1.07 | 0.93% | 115.51 | 116.94 | 114.46 |
Jan 25, 2023 | 115.45 | 1.60 | 1.41% | 113.85 | 116.29 | 113.84 |
Jan 24, 2023 | 113.39 | 3.30 | 3.00% | 110.09 | 113.79 | 110.09 |
Jan 23, 2023 | 110.98 | 1.71 | 1.56% | 109.27 | 111.38 | 108.74 |
Jan 20, 2023 | 110.47 | 1.35 | 1.24% | 109.12 | 110.86 | 108.49 |
Jan 19, 2023 | 108.78 | -1.10 | -1.00% | 109.88 | 109.96 | 108.60 |
Jan 18, 2023 | 110.28 | -0.81 | -0.73% | 111.09 | 111.73 | 110.15 |
Jan 17, 2023 | 111.36 | 0.36 | 0.32% | 111.00 | 112.79 | 109.88 |
Jan 13, 2023 | 112.27 | 1.12 | 1.01% | 111.15 | 114.58 | 110.75 |
Jan 12, 2023 | 112.91 | 2.89 | 2.63% | 110.02 | 113.43 | 108.97 |
Jan 11, 2023 | 110.68 | -0.47 | -0.42% | 111.15 | 112.46 | 108.79 |
Jan 10, 2023 | 110.79 | 3.99 | 3.74% | 106.80 | 111.79 | 106.11 |
Jan 9, 2023 | 106.58 | -2.13 | -1.96% | 108.71 | 109.86 | 105.28 |
Jan 6, 2023 | 108.31 | 2.12 | 2.00% | 106.19 | 109.07 | 106.19 |
BioMarin Pharmaceutical Inc Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Årlig
- Pr kvartal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total omsætning | 1116.85 | 1313.65 | 1491.21 | 1704.05 | 1860.45 | 1846.28 |
Omsætning | 1116.85 | 1313.65 | 1491.21 | 1704.05 | 1860.45 | 1846.28 |
Kost af omsætning, Total | 209.62 | 241.786 | 315.264 | 359.466 | 524.272 | 470.515 |
Bruttofortjeneste | 907.234 | 1071.86 | 1175.95 | 1344.58 | 1336.18 | 1375.76 |
Totale Driftsudgifter | 1920.28 | 1328.35 | 1614.74 | 1804.51 | 1897.22 | 1928.62 |
Salgs/Generelle/Admin. Udgifter, Total | 472.976 | 565.167 | 610.014 | 675.665 | 737.784 | 760.923 |
Forskning & Udvikling | 661.905 | 610.753 | 696.328 | 715.007 | 628.116 | 628.793 |
Depreciation / Amortization | 30.2 | 36.2 | 30.3 | 53.5 | 62.2 | 61.9 |
Renteudgift (Indkomst) - Netto Drift | 3.617 | -10.831 | -5.661 | 5.259 | -0.115 | -1.548 |
Usædvanlig Udgift (Indkomst) | 599.118 | -125 | -50 | -25 | -59.495 | 0 |
Other Operating Expenses, Total | -57.153 | 10.271 | 18.491 | 20.608 | 4.458 | 8.033 |
Driftsindtægter | -803.429 | -14.7 | -123.524 | -100.457 | -36.765 | -82.341 |
Renteindkomst (Udgift), Netto Ikke-Drift | -32.55 | -29.145 | -21.386 | -1.299 | -12.705 | -4.855 |
Andre, Netto | 4.929 | 7.97 | 2.205 | 6.945 | 7.148 | 11.846 |
Netto Indkomst Før Skat | -831.05 | -35.875 | -142.705 | -94.811 | -42.322 | -75.35 |
Netto Indkomst Efter Skat | -630.21 | -74.742 | -77.211 | -23.848 | 4.561 | -68 |
Netto Indkomst Før Ekstra Ting | -630.21 | -74.742 | -77.211 | -23.848 | 4.561 | -68 |
Netto Indkomst | -630.21 | -117.042 | -77.211 | -23.848 | 859.1 | -64.08 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -630.21 | -74.742 | -77.211 | -23.848 | 4.561 | -68 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -630.21 | -117.042 | -77.211 | -23.848 | 859.1 | -64.08 |
Fortyndet Netto Indkomst | -630.21 | -117.042 | -77.211 | -23.848 | 859.1 | -64.08 |
Fortyndet Vægtet Gennemsnit Aktier | 165.985 | 174.427 | 177.061 | 179.039 | 191.678 | 182.852 |
Fortyndet EPS Uden Ekstraordinære Ting | -3.79679 | -0.4285 | -0.43607 | -0.1332 | 0.0238 | -0.37189 |
Fortyndet Normaliseret EPS | -1.45063 | -0.89431 | -0.61962 | -0.22396 | -0.17796 | -0.37189 |
Totale Ekstraordinære Ting | -42.3 | 0 | 854.539 | 3.92 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total omsætning | 486.03 | 501.693 | 408.742 | 449.81 | 519.359 |
Omsætning | 486.03 | 501.693 | 408.742 | 449.81 | 519.359 |
Kost af omsætning, Total | 120.166 | 127.062 | 103.537 | 119.75 | 116.965 |
Bruttofortjeneste | 365.864 | 374.631 | 305.205 | 330.06 | 402.394 |
Totale Driftsudgifter | 460.944 | 490.021 | 461.961 | 515.69 | 382.032 |
Salgs/Generelle/Admin. Udgifter, Total | 174.318 | 184.161 | 183.333 | 217.563 | 194.619 |
Forskning & Udvikling | 148.725 | 161.107 | 157.869 | 161.092 | 160.836 |
Depreciation / Amortization | 15.4 | 15.5 | 15.4 | 15.6 | 15.6 |
Usædvanlig Udgift (Indkomst) | 0 | 0 | 0 | 0 | -108 |
Other Operating Expenses, Total | 2.335 | 2.191 | 1.822 | 1.685 | 2.012 |
Driftsindtægter | 25.086 | 11.672 | -53.219 | -65.88 | 137.327 |
Renteindkomst (Udgift), Netto Ikke-Drift | -2.716 | 0.479 | -1.866 | -0.752 | -1.986 |
Andre, Netto | 0.858 | 2.005 | 8.925 | 0.058 | -1.154 |
Netto Indkomst Før Skat | 23.228 | 14.156 | -46.16 | -66.574 | 134.187 |
Netto Indkomst Efter Skat | 17.371 | 12.941 | -36.494 | -61.818 | 120.798 |
Netto Indkomst Før Ekstra Ting | 17.371 | 12.941 | -36.494 | -61.818 | 120.798 |
Netto Indkomst | 17.371 | 12.941 | -36.494 | -57.898 | 120.798 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 17.371 | 12.941 | -36.494 | -61.818 | 120.798 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 17.371 | 12.941 | -36.494 | -57.898 | 120.798 |
Fortyndet Netto Indkomst | 17.371 | 12.941 | -36.494 | -57.898 | 120.798 |
Fortyndet Vægtet Gennemsnit Aktier | 184.365 | 185.427 | 183.214 | 183.56 | 194.886 |
Fortyndet EPS Uden Ekstraordinære Ting | 0.09422 | 0.06979 | -0.19919 | -0.33677 | 0.61984 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Fortyndet Normaliseret EPS | 0.09422 | 0.06979 | -0.19919 | -0.33677 | 0.12096 |
Totale Ekstraordinære Ting | 3.92 |
- Årlig
- Pr kvartal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Totale Nuværende Aktiver | 1421.79 | 2207.14 | 2056.22 | 1942.14 | 2342.22 | 2274.39 |
Likvider og Kortsigtede Investeringer | 789.677 | 1395.97 | 1084.31 | 753.807 | 1065.39 | 1013.88 |
Likvider & Lignende | 408.33 | 598.028 | 493.982 | 437.446 | 649.158 | 587.276 |
Kortsigtede Investeringer | 381.347 | 797.94 | 590.326 | 316.361 | 416.228 | 426.599 |
Totale Tilgodehavender, Netto | 215.28 | 261.365 | 342.633 | 377.404 | 448.351 | 373.399 |
Accounts Receivable - Trade, Net | 215.28 | 261.365 | 342.633 | 377.404 | 448.351 | 373.399 |
Total Inventory | 355.126 | 475.775 | 530.871 | 680.275 | 698.548 | 776.669 |
Other Current Assets, Total | 61.708 | 74.036 | 98.403 | 130.657 | 129.934 | 110.442 |
Total Assets | 4023.69 | 4633.12 | 4427.13 | 4690.04 | 5848.02 | 6003.33 |
Property/Plant/Equipment, Total - Net | 798.768 | 896.7 | 948.682 | 1070.3 | 1089.58 | 1081.88 |
Property/Plant/Equipment, Total - Gross | 1141.36 | 1303.43 | 1421.32 | 1619.4 | 1725.18 | 1802.45 |
Accumulated Depreciation, Total | -342.594 | -406.734 | -472.635 | -549.1 | -635.595 | -720.574 |
Goodwill, Net | 197.039 | 197.039 | 197.039 | 197.039 | 196.199 | 196.199 |
Intangibles, Net | 553.78 | 517.51 | 491.808 | 456.58 | 417.271 | 388.652 |
Long Term Investments | 572.711 | 385.785 | 235.864 | 411.978 | 285.473 | 507.793 |
Other Long Term Assets, Total | 479.601 | 428.947 | 497.52 | 611.997 | 1517.28 | 1554.42 |
Total Current Liabilities | 439.31 | 816.518 | 523.241 | 932.503 | 492.548 | 539.822 |
Payable/Accrued | 198.53 | 161.652 | 208.119 | 240.981 | 191.429 | 193.003 |
Accrued Expenses | 158.926 | 201.601 | 213.03 | 287.878 | 266.254 | 277.059 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 22.478 | 360.949 | 0 | 365.131 | 2.865 | 2.266 |
Other Current Liabilities, Total | 59.376 | 92.316 | 102.092 | 38.513 | 32 | 67.494 |
Total Liabilities | 1257.42 | 1824.46 | 1459.19 | 1567.66 | 1742.02 | 1732.58 |
Total Long Term Debt | 660.761 | 813.521 | 830.417 | 492.946 | 1079.15 | 1081.04 |
Long Term Debt | 660.761 | 813.521 | 830.417 | 486.238 | 1075.15 | 1079.08 |
Deferred Income Tax | 0 | |||||
Other Liabilities, Total | 157.344 | 194.423 | 105.53 | 142.209 | 170.319 | 111.726 |
Total Equity | 2766.27 | 2808.66 | 2967.94 | 3122.38 | 4106 | 4270.74 |
Common Stock | 0.173 | 0.176 | 0.178 | 0.18 | 0.182 | 0.184 |
Additional Paid-In Capital | 4288.11 | 4483.22 | 4669.93 | 4832.71 | 4993.41 | 5191.5 |
Retained Earnings (Accumulated Deficit) | -1520.51 | -1637.55 | -1694.13 | -1720.71 | -861.609 | -925.689 |
Other Equity, Total | -1.505 | -34.463 | -6.113 | 6.638 | -29.867 | 6.116 |
Total Liabilities & Shareholders’ Equity | 4023.69 | 4633.12 | 4427.13 | 4690.04 | 5848.02 | 6003.33 |
Total Common Shares Outstanding | 172.648 | 175.844 | 178.253 | 179.838 | 181.741 | 183.913 |
Unrealized Gain (Loss) | -2.722 | -1.917 | 3.565 | 3.889 | -1.373 | |
Capital Lease Obligations | 6.708 | 4.006 | 1.96 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 2288.77 | 2357.84 | 2311.57 | 2274.39 | 2394.02 |
Likvider og Kortsigtede Investeringer | 1087.49 | 1123.4 | 1079.48 | 1013.88 | 1056.24 |
Likvider & Lignende | 667.313 | 641.533 | 617.143 | 587.276 | 605.44 |
Kortsigtede Investeringer | 420.178 | 481.864 | 462.333 | 426.599 | 450.798 |
Totale Tilgodehavender, Netto | 396.097 | 424.419 | 374.937 | 373.399 | 430.147 |
Accounts Receivable - Trade, Net | 396.097 | 424.419 | 374.937 | 373.399 | 430.147 |
Total Inventory | 713.929 | 710.975 | 749.406 | 776.669 | 786.356 |
Other Current Assets, Total | 91.249 | 99.046 | 107.751 | 110.442 | 121.283 |
Total Assets | 5805.05 | 5898.5 | 5977.48 | 6003.33 | 6062.71 |
Property/Plant/Equipment, Total - Net | 1022.47 | 1026.58 | 1024.79 | 1035.46 | 1039.54 |
Property/Plant/Equipment, Total - Gross | 1679.77 | 1704.7 | 1724.7 | 1756.04 | 1780.71 |
Accumulated Depreciation, Total | -657.296 | -678.126 | -699.915 | -720.574 | -741.167 |
Goodwill, Net | 196.199 | 196.199 | 196.199 | 196.199 | 196.199 |
Intangibles, Net | 405.903 | 394.298 | 388.487 | 388.652 | 374.251 |
Long Term Investments | 321.127 | 350.237 | 466.618 | 507.793 | 462.827 |
Other Long Term Assets, Total | 1570.58 | 1573.35 | 1589.81 | 1600.83 | 1595.86 |
Total Current Liabilities | 430.035 | 443.344 | 514.898 | 539.822 | 490.418 |
Payable/Accrued | 165.001 | 176.073 | 203.321 | 203.467 | 187.81 |
Accrued Expenses | 209.203 | 207.005 | 241.535 | 268.861 | 214.435 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 55.831 | 60.266 | 70.042 | 67.494 | 88.173 |
Total Liabilities | 1643.04 | 1656.93 | 1711.33 | 1732.58 | 1671.39 |
Total Long Term Debt | 1076.13 | 1077.11 | 1078.09 | 1079.08 | 1080.06 |
Long Term Debt | 1076.13 | 1077.11 | 1078.09 | 1079.08 | 1080.06 |
Other Liabilities, Total | 136.881 | 136.471 | 118.335 | 113.686 | 100.913 |
Total Equity | 4162.01 | 4241.57 | 4266.15 | 4270.74 | 4391.31 |
Common Stock | 0.183 | 0.183 | 0.184 | 0.184 | 0.185 |
Additional Paid-In Capital | 5010.62 | 5083.83 | 5133.74 | 5191.5 | 5206.29 |
Retained Earnings (Accumulated Deficit) | -844.238 | -831.297 | -867.791 | -925.689 | -804.891 |
Unrealized Gain (Loss) | 2.387 | 1.821 | 1.218 | -1.373 | -9.264 |
Other Equity, Total | -6.941 | -12.967 | -1.204 | 6.116 | -1.002 |
Total Liabilities & Shareholders’ Equity | 5805.05 | 5898.5 | 5977.48 | 6003.33 | 6062.71 |
Total Common Shares Outstanding | 182.671 | 183.322 | 183.567 | 183.913 | 184.902 |
- Årlig
- Pr kvartal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Netto indkomst/Startlinje | -630.21 | -117.042 | -77.211 | -23.848 | 859.1 | -64.08 |
Likvider Fra Driftsaktiviteter | -227.837 | -8.757 | 20.208 | 48.262 | 85.365 | 304.536 |
Likvider Fra Driftsaktiviteter | 96.912 | 87.861 | 95.671 | 105.3 | 105.172 | 108.039 |
Deferred Taxes | -228.054 | 44.464 | -68.378 | -82.76 | -888.907 | -15.608 |
Ikke-Likvide Ting | 693.791 | 69.923 | 119.546 | 150.662 | 234.417 | 210.151 |
Cash Taxes Paid | 95.857 | 23.895 | 16.676 | 9.726 | 8.977 | 18.153 |
Likvid Rente Betalt | 8.643 | 8.544 | 11.623 | 8.552 | 12.178 | 10.395 |
Ændringer i Driftskapital | -160.276 | -93.963 | -49.42 | -101.092 | -224.417 | 66.034 |
Likvider fra Investeringsaktiviteter | -484.047 | -305.459 | 264.351 | -31.026 | -53.621 | -366.313 |
Kapitaludgifter | -148.38 | -199.219 | -144.62 | -163.406 | -137.519 | -119.225 |
Andre Investerings-Cash-Flow-Ting, Total | -335.667 | -106.24 | 408.971 | 132.38 | 83.898 | -247.088 |
Likvider fra Financieringsaktiviteter | 727.108 | 507.145 | -388.007 | -74.674 | 181.118 | -0.048 |
Financiering af Cash-Flow-Ting | -60.057 | -35.427 | -80.542 | -101.198 | -44.638 | -46.203 |
Udstedelse (Pensionering) af Aktier, Netto | 787.165 | 60.859 | 67.488 | 31.611 | 21.913 | 49.194 |
Udenlandsk Børs Effekter | -3.934 | -3.231 | -0.598 | 0.902 | -1.15 | -0.057 |
Netto Ændring i Likviditet | 11.29 | 189.698 | -104.046 | -56.536 | 211.712 | -61.882 |
Udstedelse (Pensionering) af Gæld, Netto | 481.713 | -374.953 | -5.087 | 203.843 | -3.039 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 17.371 | 30.312 | -6.182 | -64.08 | 120.798 |
Cash From Operating Activities | 113.512 | 196.296 | 293.356 | 304.536 | -45.431 |
Cash From Operating Activities | 27.983 | 55.214 | 82.053 | 108.039 | 27.343 |
Deferred Taxes | 3.335 | 1.204 | -12.02 | -15.608 | 4.8 |
Non-Cash Items | 56.553 | 111.414 | 163.355 | 210.151 | -61.68 |
Cash Taxes Paid | 2.998 | 10.159 | 15.531 | 18.153 | 1.316 |
Cash Interest Paid | 1.465 | 5.195 | 6.673 | 10.395 | 1.422 |
Changes in Working Capital | 8.27 | -1.848 | 66.15 | 66.034 | -136.692 |
Cash From Investing Activities | -70.788 | -191.045 | -310.892 | -366.313 | 87.782 |
Capital Expenditures | -28.254 | -54.506 | -74.866 | -119.225 | -30.675 |
Other Investing Cash Flow Items, Total | -42.534 | -136.539 | -236.026 | -247.088 | 118.457 |
Cash From Financing Activities | -24.364 | -13.413 | -14.444 | -0.048 | -25.28 |
Financing Cash Flow Items | -29.097 | -39.112 | -44.829 | -46.203 | -32.949 |
Issuance (Retirement) of Stock, Net | 5.817 | 27.64 | 32.877 | 49.194 | 8.235 |
Issuance (Retirement) of Debt, Net | -1.084 | -1.941 | -2.492 | -3.039 | -0.566 |
Foreign Exchange Effects | -0.205 | 0.537 | -0.035 | -0.057 | 1.093 |
Net Change in Cash | 18.155 | -7.625 | -32.015 | -61.882 | 18.164 |
Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
---|---|---|---|---|---|---|
PRIMECAP Management Company | Investment Advisor | 9.4838 | 17625505 | -52980 | 2022-09-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.1613 | 17026106 | 263453 | 2022-09-30 | LOW |
Dodge & Cox | Investment Advisor/Hedge Fund | 7.9494 | 14773963 | -233100 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.3137 | 9875458 | 113895 | 2022-09-30 | LOW |
Baker Bros. Advisors LP | Hedge Fund | 4.1004 | 7620494 | 0 | 2022-09-30 | LOW |
Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 3.0607 | 5688259 | 129970 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.8402 | 5278438 | -117928 | 2022-09-30 | LOW |
Viking Global Investors LP | Investment Advisor/Hedge Fund | 2.7437 | 5099164 | 46571 | 2022-09-30 | MED |
Capital Research Global Investors | Investment Advisor | 2.6563 | 4936740 | 1394 | 2022-09-30 | LOW |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 2.2221 | 4129724 | -71509 | 2022-09-30 | LOW |
Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 1.9131 | 3555555 | 271555 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.353 | 2514523 | 42707 | 2022-09-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.2642 | 2349540 | 223693 | 2021-12-31 | LOW |
Parnassus Investments, LLC | Investment Advisor | 1.2583 | 2338529 | -227551 | 2022-12-31 | LOW |
Barclays Bank PLC | Investment Advisor | 1.1309 | 2101767 | 182659 | 2022-09-30 | MED |
Palo Alto Investors LP | Hedge Fund | 1.0634 | 1976265 | -85108 | 2022-09-30 | LOW |
Millennium Management LLC | Hedge Fund | 1.0085 | 1874272 | 348269 | 2022-09-30 | HIGH |
Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.9306 | 1729432 | 1607478 | 2022-09-30 | HIGH |
OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 0.924 | 1717310 | 17600 | 2022-09-30 | LOW |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.7732 | 1437057 | -102057 | 2022-09-30 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com GroupHandlende
Månedlkige, aktive klienter
Månedlig investeringsvolumen
Hævet hver måned
Handelslommeregner
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
BioMarin Company profile
Om BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc er en bioteknologisk virksomhed. Virksomheden udvikler og markedsfører terapier til mennesker med alvorlige og livstruende sjældne sygdomme og medicinske tilstande. Virksomhedens portefølje består af kommercielle produkter og flere kliniske og prækliniske produktkandidater til behandling af forskellige sygdomme. Selskabets kommercielle produkter omfatter Aldurazyme (laronidase), Brineura (cerliponase alfa), Kuvan (sapropterin dihydrochlorid), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Vimizim (elosulfase alfa) og Voxzogo (vosoritid). Virksomhedens pipeline omfatter Valoctocogene Roxaparvovec til behandling af svær hæmofili A, Vosoritid til behandling af akondroplasi, BMN 307 til behandling af phenylketonuri (PKU) og BMN 331 til behandling af hereditært angioødem (HAE).
Industry: | Biopharmaceuticals |
105 Digital Dr
NOVATO
CALIFORNIA 94949
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 485.000+ handlende over hele verden, der valgte at handle hos Capital.com